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Crystal structure of the N-myristoylated
lipopeptide-bound MHC class I complex
Daisuke Morita1,2, Yukie Yamamoto1,2, Tatsuaki Mizutani1, Takeshi Ishikawa3, Juri Suzuki4, Tatsuhiko Igarashi5,
Naoki Mori6, Takashi Shiina7, Hidetoshi Inoko7, Hiroaki Fujita8, Kazuhiro Iwai8, Yoshimasa Tanaka9,
Bunzo Mikami10 & Masahiko Sugita1,2
The covalent conjugation of a 14-carbon saturated fatty acid (myristic acid) to the
amino-terminal glycine residue is critical for some viral proteins to function. This protein
lipidation modiﬁcation, termed N-myristoylation, is targeted by host cytotoxic T lymphocytes
(CTLs) that speciﬁcally recognize N-myristoylated short peptides; however, the molecular
mechanisms underlying lipopeptide antigen (Ag) presentation remain elusive. Here we
show that a primate major histocompatibility complex (MHC) class I-encoded protein is
capable of binding N-myristoylated 5-mer peptides and presenting them to speciﬁc CTLs. A
high-resolution X-ray crystallographic analysis of the MHC class I:lipopeptide complex reveals
an Ag-binding groove that is elaborately constructed to bind N-myristoylated short peptides
rather than prototypic 9-mer peptides. The identiﬁcation of lipopeptide-speciﬁc, MHC class
I-restricted CTLs indicates that the widely accepted concept of MHC class I-mediated
presentation of long peptides to CTLs may need some modiﬁcations to incorporate a novel
MHC class I function of lipopeptide Ag presentation.
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R
esearch carried out over the past three decades has
unravelled the molecular and structural bases of
cell-mediated immunity, resulting in the establishment
of a central paradigm for antigen (Ag) presentation in which
major histocompatibility complex (MHC) class I and class II
molecules bind peptide Ags and present them to CD8þ and
CD4þ T cells, respectively, bearing clonotypic ab T-cell
receptors (TCRs)1. The repertoire of Ags targeted by ab T cells
has been further expanded to include lipid Ags, such as fatty acids
and glycolipids, which are captured and presented by non-MHC-
encoded group 1 CD1 molecules2. These two arms of the adaptive
immune system, one directed against peptides and the other
against lipids, may function cooperatively for effective host
defense against microbial infections. Indeed, both peptide-speciﬁc
and lipid-speciﬁc cytotoxic T lymphocytes (CTLs) have been
identiﬁed as having the potential to eliminate Mycobacterium
tuberculosis-infected cells3.
Unlike bacteria, viruses do not produce their own lipids;
however, some viral proteins are lipid modiﬁed by using the
host cellular machinery4–6. For example, human and simian
immunodeﬁciency viruses (HIV and SIV) borrow host-derived
N-myristoyltransferase and its substrate myristoyl-CoA, to
couple a 14-carbon saturated fatty acid (myristic acid) to the
N-terminal glycine residue of the Nef protein. This
lipidation process, referred to as N-myristoylation, is essential
for the Nef protein to downregulate the cell surface expression
of MHC class I molecules, thereby inhibiting the efﬁcient
induction of virus-speciﬁc CTLs7,8. On the other hand,
the ﬁndings of our recent studies have indicated that the
adaptive immune system is equipped with CTLs capable of
sensing the lipid modiﬁcation reaction of the Nef protein9,10. The
rhesus macaque CD8þ CTL line 2N5.1 speciﬁcally recognizes the
N-myristoylated 5-mer peptide (C14-Gly-Gly-Ala-Ile-Ser;
C14nef5) derived from the SIV Nef protein. Furthermore,
N-myristoylated Nef peptide-speciﬁc T cells were found to
expand signiﬁcantly in the peripheral blood of SIV-infected
monkeys and the plasma viral load in the infected monkeys
correlated reciprocally with the number of circulating
lipopeptide-speciﬁc T cells. These ﬁndings suggest that
besides peptides (presented by MHC class I) and lipids
(presented by group 1 CD1), lipopeptides may comprise a
novel chemical class of Ags targeted by CTLs with implications in
the host defense against viral infection; however, the identity of
the lipopeptide Ag-presenting molecules currently remains
unknown.
In the present study, we show that the classical MHC class
I-encoded protein Mamu-B*098 captures C14nef5 and interacts
with speciﬁc TCRs, thereby supporting the recognition of
C14nef5 by 2N5.1 T cells. The capacity of the Mamu-B*098
protein to function as a lipopeptide Ag-presenting molecule is
further substantiated by a high-resolution X-ray crystallographic
analysis of the trimeric complex of B*098 heavy chains,
b2-microglobulin (b2m) and C14nef5. The myristoyl group of
the lipopeptide is accommodated in the relatively large B pocket
lined with hydrophobic amino acid residues and the
carboxy-terminal serine residue is anchored at the small F pocket
via multiple hydrogen bonds, leaving the second and fourth
amino acid residues exposed externally. Furthermore, a conduit
between A and B pockets in Mamu-B*098 is spatially
disconnected, making the A pocket isolated and unoccupied.
These structural features have not been recognized previously for
other MHC class I molecules that bind prototypic 9-mer peptides.
Taken together, these results suggest that MHC class I molecules
may have evolved to include those binding N-myristoylated short
peptides, thereby assisting CTLs to speciﬁcally sense the
N-myristoylation of viral proteins.
Results
Identiﬁcation of a lipopeptide Ag-presenting molecule. The
recognition of C14nef5 by 2N5.1 requires the presence of
irradiated peripheral blood mononuclear cells (PBMCs)9, which
suggests that PBMCs express a molecule capable of binding
C14nef5 and presenting it to 2N5.1. To obtain an insight into its
molecular identity, we generated several hundred monoclonal
antibodies that recognized rhesus PBMCs and tested their abilities
to block the presentation of C14nef5 to 2N5.1. Two blocking
monoclonal antibodies, MB217 and MB226, were isolated
(Supplementary Fig. 1a) and a series of biochemical and cellular
analyses revealed that MB217 speciﬁcally recognized rhesus b2m,
whereas MB226 reacted broadly with rhesus MHC class I
molecules (Supplementary Fig. 1b–e). As b2m-associated MHC
class I molecules may restrict the recognition of C14nef5 by
2N5.1, we isolated an array of rhesus MHC (Mamu) class I
complementary DNA clones from a donor with the potential to
present C14nef5 to 2N5.1 and transfected each cDNA clone into
the monkey kidney epithelial cell line LLC-MK2. The ability of
the cell transfectants to present C14nef5 to 2N5.1 was then
examined. None of the cell transfectants exhibited the Ag
presentation capacity, except those expressing Mamu-B*098,
which stimulated 2N5.1 cells to produce interferon-g (IFN-g) in
the presence of C14nef5, but not in its absence (Fig. 1a). These
results strongly suggested that the Mamu-B*098 protein may
function as a lipopeptide Ag-presenting molecule.
To address this possibility directly, cell-free assays were
performed with a soluble recombinant Mamu-B*098 protein.
Using a biolayer interferometry technique, the physical interactions
between C14nef5 and a layer of immobilized protein on the
biosensor tip were demonstrated for Mamu-B*098 but not for the
control protein Mamu-A*02 (Fig. 1b). Furthermore, plate-coated
Mamu-B*098, but not Mamu-A*02, was sufﬁcient for stimulating
2N5.1 to produce IFN-g in response to C14nef5 (Fig. 1c). The non-
antigenic mutant, C14-GGAAS, in which the fourth isoleucine
residue was replaced by alanine, bound to B*098 (Fig. 1b) but
failed to stimulate 2N5.1 even in the presence of Mamu-B*098
(Fig. 1c), suggesting that the isoleucine residue served as a T-cell
epitopic determinant. Furthermore, surface plasmon resonance
(SPR)-binding experiments revealed that a soluble TCR ab dimer
derived from 2N5.1 interacted with C14nef5-loaded, but not with
C14-GGAAS-loaded, Mamu-B*098, with an afﬁnity that was
similar to that for peptide-speciﬁc TCR–MHC interactions
(Fig. 1d)11. Taken together, these results provide compelling
evidence that the Mamu-B*098 protein functions as a lipopeptide
Ag-presenting molecule capable of binding C14nef5 and
presenting it to T cells bearing speciﬁc ab TCRs.
Structure of Mamu-B*098. The amino acid sequence of
Mamu-B*098 is very similar to those of conventional MHC
class I molecules, such as Mamu-B*17 in rhesus macaques and
HLA-B27 in humans, which mediate the presentation of 8- to
10-mer peptides to T cells (Fig. 1e), and provides no reasonable
insight into how the MHC class I protein binds N-myristoylated
5-mer peptides that are structurally and chemically distinct from
prototypic MHC class I-presented peptides.
To elucidate the molecular basis underlying lipopeptide Ag
presentation, we sought to clarify the high-resolution X-ray
crystal structure of the Mamu-B*098:C14nef5 complex. The
ectodomain of the Mamu-B*098 heavy chain and rhesus b2m
were produced in Escherichia coli as inclusion bodies and the
puriﬁed recombinant proteins were refolded in the presence of
C14nef5. In our initial attempts, proper refolding occurred
inefﬁciently, which was most probably due to aberrant disulﬁde
bond formation involving a cysteine residue at position 167
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(Fig. 1e, shown with an open arrowhead). The introduction of the
cysteine to serine mutation at this position resulted in improved
refolding efﬁciency. This mutation affected neither the overall
secondary structure nor the ability of Mamu-B*098 to present
C14nef5 to 2N5.1 (data not shown). Thus, the amino acid


















































































































































































































































HLA- B*2709 GS--HSMRYFHTS--VSRPGRGEPRFITVGYVDDTLFVRFDSDAASPREEPRAPWIEQE-GPEYWDRETQICKAKAQTDREDLRTLLRYYNQSE-A 90
Human CD1a ADGLKEPLSFHVTWIASFYNHSWKQNLVSGWLSDLQTHTWDSNSSTI--VFLCPWSRGNFSNEEWKELETLFRIR--TIR-SFEGIRRYAHELQFE 91
Mamu-B*098 GSHTLQTMSGCDLGPDGRLLRGYYQQAYDGRDYIALNEDLRSWTAA----DEAAQNTQRKWEAAGVAEQWRAYLEGECLECLRRYLENGKETLQRA 182
Mamu-B*1701 GSHTIQKMYGCDLGPDGRLLRGYHQSAYDGKDYIALNGDLRSWTAA----DMAAQNTQRKWEGNRYAERFRAYLEGECLEWLRRYLENGKETLQRA 182
HLA- B*2709 GSHTLQNMYGCDVGPDGRLLRGYHQHAYDGKDYIALNEDLSSWTAA----DTAAQITQRKWEAARVAEQLRAYLEGECVEWLRRYLENGKETLQRA 182
Human CD1a YPFEIQVTGGCELH-SGKVSGSFLQLAYQGSDFVSFQNN--SWLPYPVAGNMAKHFCKVLNQNQHENDITHNLLSDTCPRFILGLLDAGKAHLQRQ 184
Mamu-B*098 EPPKTHVTHHPVSD-HEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPGGDGTFQKWGAVVVPSGEEQRYTCHVQHEGLP-EPLTLRW 274
Mamu-B*1701 DPPKTHVTHHPVSD-HEATLRCWALGFYPAEITLTWQRDGEEQTQDTEFVETRPGGDGTFQKWGAVVVPSGEEQRYTCHVQHEGLP-EPLTLRW 274
HLA- B*2709 DPPKTHVTHHPISD-HEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLP-KPLTLRW 274
Human CD1a VKPEAWLSHGPSPGPGHLQLVCHVSGFYPKPVWVMWMR-GEQEQQGTQRGDILPSADGTWYLRATLEVAAGEAADLSCRVKHSSLEGQDIVLYW 277
Figure 1 | Identiﬁcation of Mamu-B*098 as a lipopeptide Ag-presenting molecule. (a) LLC-MK2 cells transfected with each of the rhesus MHC class I
genes were tested for their ability to present C14nef5 to 2N5.1. Only LLC-MK2 cells expressing Mamu-B*098 stimulated 2N5.1 to produce IFN-g in the
presence of C14nef5. PBMCs obtained from a donor with the potential to present C14nef5 to 2N5.1 were used as a positive control. Experiments were
performed in triplicate. Mean values with s.e.m. are shown. (b) The binding of lipopeptide Ags to recombinant b2m-linked Mamu-B*098 and Mamu-A*02
proteins was monitored by biolayer interferometry. Representative data from three independent experiments are shown. Mamu-A*02, a rhesus MHC class
I allele known to bind 9-mer peptides, was used as a negative control. (c) Plate-coated MHC class I molecules were tested for their ability to present
lipopeptide Ags to 2N5.1. The Ag-speciﬁc T-cell response was assessed by measuring the amount of IFN-g released into the culture medium. Mean values
with s.e.m. are shown. (d) The high-afﬁnity interaction of the 2N5.1 TCR with C14nef5-loaded Mamu-B*098 was demonstrated by SPR-binding assays,
whereas no interaction was detected with C14-GGAAS-loaded and unloaded Mamu-B*098 molecules, as well as YY9 peptide-loaded Mamu-A*02
molecules. The original data (coloured as indicated) are depicted with the curve ﬁt (grey) overlaid. The steady-state afﬁnity plot (inset) is also shown.
Three independent experiments were performed and mean equilibrium-dissociation constant (KD) values ±s.d. are shown. (e) Amino acid sequences of
Mamu-B*098, HLA-B*27:09, Mamu-B*17:01 and human CD1a are shown. The a1 and a2 domains of Mamu-B*098 exhibit 81.1%, 80.6% and 20.6%
sequence homology to the corresponding domains of HLA-B27, Mamu-B*17 and human CD1a, respectively. Solid and open triangles indicate paired and
unpaired cysteine residues, respectively. The residue for N-glycosylation is indicated with an asterisk.
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We determined the crystal structure of the Mamu-
B*098:C14nef5 complex at a resolution of 1.76 Å (Table 1 and
Supplementary Fig. 2). The overall structure of Mamu-B*098 was
almost indistinguishable from that of other MHC class I
molecules, which were characterized by two semisymmetrical
domains, a1 and a2, which formed a b-sheet platform topped by
two semiparallel a-helices (Fig. 2a)12. The a1/a2-fold of Mamu-
B*098 exhibited a high degree of structural similarity with those
of HLA-B27 and Mamu-B*17 with root-mean-square deviations
(r.m.s.d.) of 0.76 and 0.82 Å, respectively13,14, and the groove
width, as measured by the distance between the opposing a1 and
a2 helices, was similar among the MHC-B molecules (Fig. 2b).
Continuous electron density corresponding to C14nef5 was
observed in the Ag-binding groove, thus providing direct
evidence for the capacity of Mamu-B*098 to bind the
lipopeptide Ag (Fig. 2c).
As for other MHC class I molecules, six pocket structures,
designated A through F, were identiﬁed in the Ag-binding groove
of Mamu-B*098 (Fig. 2d). The myristoyl group and C-terminal
serine residue (Ser5) were buried deeply in the groove and
interacted primarily with the B pocket and F pocket, respectively,
forcing the central three residues of the peptide chain, in
particular Gly2 and Ile4, to protrude out of the groove and into
the solvent (Fig. 2c,e). These structural features were consistent
with the prediction deduced from the T-cell assays10.
Accommodation of the myristoyl group in the B pocket. The
acyl chain of C14nef5 did not gain access to the A pocket and was
packed in a U-shaped conﬁguration in the B pocket, which was
lined with an array of hydrophobic or non-charged amino acid
residues, including Tyr7, Phe22, Val24, Met45, Gln63, Val67,
Ala70 and Phe74 (Fig. 3a). Numerous intermolecular van der
Waals (VDW) forces and those established within the acyl chain
supported its stable accommodation within the pocket
(Supplementary Fig. 3 and Table 1). Besides its hydrophobic
properties and low electrostatic potential (Supplementary Fig. 4),
the Mamu-B*098 B pocket was also marked by its ample
cavity (250Å3), which was roughly 1.5-fold larger than that of
the corresponding B pockets of other known MHC class I
molecules (Fig. 3b). The side chains of His9, Lys70 and Tyr99
of HLA-B27, as well as those of Tyr9, Lys97 and Tyr99 of
Mamu-B*17, protruded into the cavity; however, the amino acid
residues at these positions (Ser9, Ala70, Thr97 and Ser99) were all
small in Mamu-B*098, allowing the folded myristoyl group to ﬁt
in the B pocket (Fig. 3b).
The myristoyl group made a sharp U-turn instead of extending
into the A pocket, thereby leaving the A pocket unoccupied, and
the view from the A pocket towards the B pocket pointed to a
highly constricted conduit between the two pockets (Fig. 3c, left
panel). The bulky side chain of Gln63, as well as the side chains of
Tyr7 and Tyr159, which were conserved among human and
rhesus MHC class I molecules, protruded into the channel.
Furthermore, the salt bridge that was established between
Arg66 and Glu163 overhung the channel, making the opening
as narrow as 4 4Å2, a size that hardly allowed any peptide
chains to pass through15. As a comparison, HLA-B27 had a bulky
amino acid residue (Glu) at position 63, but lacked a salt bridge
between positions 66 and 163 (Fig. 3c, middle panel), whereas
Mamu-B*17 retained the salt bridge, but lacked the bulky residue
at position 63 (right panel), thereby sustaining a structure that
allowed the N-terminal residue of 9-mer peptides to gain access
to the A pocket. The bulky side chains of Gln63 and Arg66 in
Mamu-B*098 also contributed to the sidewall of the B pocket
and established VDW interactions with the myristoyl group
of bound lipopeptides (Fig. 3a and Supplementary Table 1).
These structural features have not been reported in previously
studied 9-mer peptide-presenting MHC class I alleles12 and we
assumed that it may be difﬁcult for Mamu-B*098 to bind
conventional 9-mer peptides in a similar manner to that of other
known MHC class I molecules.
Accommodation of the C-terminal residue in the F pocket. The
C-terminal Ser residue (Ser5) of C14nef5 was anchored at the
F pocket, which was smaller in size primarily due to the bulky
side chain of Gln116 reducing the depth of the pocket (Fig. 4a).
Thus, the C-terminal residue potentially accommodated in the
F pocket is likely to be a relatively small amino acid residue, such
as serine or threonine, constituting the N-myristoylation motif16,
rather than the bulky amino acid residues found in most MHC
class I-presented 9-mer peptides17. The main chain of Ser5 of
C14nef5 was stabilized by a network of hydrogen bonds,
involving Ser77, Asn80, Tyr84, Thr143 and Lys146, which is
commonly found in peptide-bound MHC class I molecules12–14,
whereas the side chain of Ser5 established a hydrogen bond with
Gln116 (Fig. 4b).
Spatial conﬁguration of the bound lipopeptide. Besides Ser5,
the main chain of Ile4 of C14nef5 was stabilized by a hydrogen
bond with Trp147 and the carbonyl oxygen of Ala3 made
water-mediated hydrogen bonds with Tyr114 and Gln116
(Fig. 4b, right panel). As a result of these speciﬁc interactions, the
spatial conﬁguration of the three C-terminal amino acid residues
(Ala3, Ile4 and Ser5) of C14nef5 bound to Mamu-B*098 was
nearly identical to that of the corresponding residues of
conventional 8- to 10-mer peptides bound to known MHC class I
molecules (Fig. 5). In contrast, Gly1 of C14nef5 deviated
signiﬁcantly below the level of the corresponding amino acid
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Resolution (Å) 50–1.76 (1.79–1.76)
Rmerge 0.042 (0.532)
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Redundancy 2.61 (2.5)
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Bond lengths (Å) 0.008
Bond angles () 1.11
EDO, 1,2-ethanediol; MYR, myristic acid; R.m.s.d., root-mean-square deviation; TRS, 2-Amino-2-
hydroxymethyl-propane-1,3-diol.
Data were collected from a single crystal.
*The Highest resolution shell is shown in parentheses.
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residue (Fig. 5b, bottom panel). As the N-myristoylated Gly1 and
C-terminal Ser5 residues were both buried deeply in the groove
(Fig. 3c, right panel), this superimposed image also pointed to the
primary role of the elevated middle three amino acid residues, in
particular Gly2 and Ile4 with their side chains directed upwards,
as T-cell epitopes.
Discussion
The biology of MHC class I molecules represents one of the
central foci for modern immunology research. Key ﬁndings
obtained by pioneering studies, including the milestone discovery
of the X-ray crystallographic structure of the ligand-bound
HLA-A2 molecule, have established that MHC class I molecules
bind 8- to 10-mer peptides and present them to speciﬁc
CTLs18,19. The present study has provided functional and
structural evidence to show that MHC class I molecules have
evolved to include those that bind N-myristoylated short peptides
and present them to speciﬁc CTLs. Therefore, the ﬁxed concept of
MHC class I-mediated presentation of long peptides to CTLs may
need some modiﬁcations to incorporate a novel MHC class I
function of lipopeptide Ag presentation.
The overall structure of Mamu-B*098 and the presence of six
pockets in the Ag-binding groove were inherent in MHC class I
molecules, whereas the large hydrophobic B pocket, small
F pocket and the partially collapsed A pocket distinguished it
from other MHC class I molecules that are known to bind long
peptides. The myristoyl group of the lipopeptide adopted a
U-shaped conﬁguration and ﬁt perfectly with the extended
B pocket. Furthermore, inter- and intramolecular VDW forces
established throughout the acyl chain synergistically reinforced its
stable binding to the B pocket. These structural features suggested
that the B pocket of Mamu-B*098 was optimally constructed, to
accommodate a myristic acid, thereby providing reasonable
explanations as to why the analogues of C14nef5, with either
shorter (C6nef5 and C10nef5) or longer (C18nef5 and C22nef5)
acyl chains, exhibit reduced or no antigenic activities10. Human
CD1a molecules are known to bind the mycobactin-like
lipopeptide JH-02215 by accommodating the acyl chain linked
to the side chain of lysine in the A’ pocket (Supplementary
Fig. 5a)20; however, the A’ pocket of CD1a and the B pocket of
Mamu-B*098 differ signiﬁcantly in their shape, size and position
(Supplementary Fig. 5b). Indeed, amino acid residues that were
predicted to establish the network of VDW interactions between
CD1a and the acyl chain of JH-02215 do not appear to correlate
with those of the interactions between Mamu-B*098 and the acyl
chain of C14nef5 (Supplementary Fig. 5c). It remains to be
addressed as to whether T cells may exist that speciﬁcally
recognize C14nef5 in the context of CD1 molecules.
The F pocket of Mamu-B*098 also appears to be favourably
used for binding N-myristoylated short peptides by taking
advantage of the presence of the conserved small amino acid
residue, either serine or threonine, at the C terminus of
lipopeptides16. Most MHC class I-presented 9-mer peptides
contain a bulky hydrophobic amino acid residue at the C
terminus that is anchored at the F pocket; however, such common
C-terminal residues may have been excluded from the small
F pocket of Mamu-B*098. C14nef5 and its Ser to Thr mutant
sustain virtually identical antigenic activities9, suggesting that the
F pocket of Mamu-B*098 accommodates threonine and serine as
well. As the myristoyl group and C-terminal serine/threonine are
critical elements commonly found in proteins that undergo
N-myristoylation21, Mamu-B*098 may have the potential to bind
various naturally occurring N-myristoylated 5-mer peptides.
To the best of our knowledge, the spatially disconnected



































































(r.m.s.d. of 0.82 Å)
HLA-A2
(r.m.s.d. of 1.0 Å)
HLA-E
(r.m.s.d. of 1.1 Å)
HLA-G
(r.m.s.d. of 1.2 Å)
MR1
(r.m.s.d. of 2.1 Å)
HFE
(r.m.s.d. of 3.7 Å)
CD1a
(r.m.s.d. of 4.2 Å)
a b
c d eTop view Side view
Figure 2 | The overall structure of the Mamu-B*098 complex. (a) Two views of the trimer complex of the ectodomain of Mamu-B*098 heavy chains
(blue), b2m (orange) and C14nef5 (yellow) are shown. (b) Superimposed images of the a1 and a2 domains of Mamu-B*098 (blue) with those of
MHC class I and MHC class I-like molecules (orange) are shown. (c) C14nef5 binding to Mamu-B*098 is demonstrated by a 2Fo-Fc map (green mesh)
contoured at 0.8s (left). The bound lipopeptide accommodated in the semi-transparent Ag-binding cavity is shown (right). (d) The surface of the
Ag-binding groove with pockets A through F is shown. (e) Solvent accessible surfaces of C14nef5 captured by Mamu-B*098 are shown for the myristoyl
group and each of the amino acid residues. Filled and unﬁlled bars indicate buried and exposed areas, respectively.
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been observed for any conventional 9-mer peptide-presenting
MHC class I molecules. The A pocket typically contributes
to stabilizing the binding of peptides by establishing a network of
hydrogen bonds between their N-terminal amide group and the
highly conserved tyrosine residues at positions 7 and 171 of MHC
class I molecules12. Therefore, the lack of easy access to the A
pocket indicates that Mamu-B*098 may be unable to bind
conventional 9-mer peptides in a similar manner to that of
known MHC class I molecules. Taken together, these structural
features suggest that the Ag-binding groove of Mamu-B*098 has
evolved to speciﬁcally bind N-myristoylated 5-mer peptides
rather than conventional long peptides.
A soluble TCR ab dimer derived from 2N5.1 interacted with
C14nef5-loaded Mamu-B*098 molecules with a similar afﬁnity
to that for peptide-speciﬁc TCR–MHC interactions (Fig. 1d).
Epitopic determinants for peptide-speciﬁc, MHC class I-restricted
TCRs often involve as many as six or seven amino acid
residues1,22,23. In contrast, the superimposed images of C14nef5
and conventional long peptides (Fig. 5a) indicated that the short
stretch of C14nef5 amino acid residues (Gly2, Ala3 and Ile4) was
only exposed externally with the potential to interact directly with
speciﬁc TCRs. Furthermore, the three consecutive amino acid
residues ﬂanked by the conserved N-terminal glycine and
C-terminal serine/threonine residues are unable to be randomly
selected for protein N-myristoylation to occur naturally in cells24,
suggesting that the diversity generated within this region may be
more limited than that achieved in MHC class I-presented
9-mer peptides. Given that N-myristoylation occurs for viral
and self proteins, this predicts the highly stringent negative
selection executed in the thymus for the elimination of self
lipopeptide-speciﬁc T cells; otherwise, autoimmune disorders
may develop, as is occasionally observed in patients with viral
infections25,26.
Despite such potential risks, the MHC class I-restricted CTL
response that speciﬁcally senses the N-myristoylation of viral
proteins may be beneﬁcial to host defenses against viral
infections. The N-myristoylation of the Nef protein is critical
for anchoring it at the plasma membrane, thereby assisting its
immunosuppressive activity. The N-myristoylated Nef protein






























































Figure 3 | Interactions with the acyl chain of the lipopeptide. (a) C14nef5 is shown in yellow as a space-ﬁlling model with the semi-transparent
Ag-binding groove of Mamu-B*098. The side chains of residues surrounding the acyl chain are shown in red. The intensity of the red colour correlates with
the degree of hydrophobicity. (b) B pockets of Mamu-B*098 (blue), HLA-B27 (light orange) and Mamu-B*17 (pink) are shown as the semi-transparent
groove and the side chains (lines) with emphasis on the non-bulky side chains (Ser9, Ala70, Thr97 and Ser99) of Mamu-B*098. C14 acyl chain or amino
acid residues accommodated in each B pocket are displayed as yellow sticks. (c) A view from the A pocket points to a narrower channel between the A and
B pockets in Mamu-B*098 (left) than in HLA-B27 (middle) and Mamu-B*17 (right). Key residues are presented as a space-ﬁlling model.
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MHC class I molecules, resulting in the inefﬁcient induction of
CTL responses to viral proteins27. The results of the present study
indicated that this well-known evasive mechanism executed by
HIV and SIV was simultaneously counterbalanced by the host
immune system through eliciting CTL responses that precisely
detected the N-myristoylation event of the Nef protein. As for a
fraction of MHC class I molecules, including HLA-C proteins28,
preliminary studies have suggested that the surface expression of
Mamu-B*098 is not downregulated in Nef-expressing HeLa cells.
Furthermore, cDNA clones with exon 6 selectively spliced out
have been isolated from primary cells, which encode the
Mamu-B*098 protein with the deletion of a long stretch of
amino acid residues in the cytoplasmic domain, including
tyrosine at position 320. As this residue is essential for
Nef-mediated downregulation to occur29, we predicted that
the surface expression of the truncated form of Mamu-B*098
may be unaffected by the Nef protein. Taken together, these
ﬁndings point to a ﬁnely tuned balance achieved by the
immunosuppressive activity of the N-myristoylated Nef protein
and MHC class I-restricted CTLs capable of sensing the
N-myristoylation event. Besides HIV and SIV, pathogenic
viruses produce N-myristoylated proteins, which are often
critical for pathogenesis30–32. The N-terminal amino acid
residues constituting the N-myristoylation motif are hard for
viruses to mutate without affecting protein function33,34.
Therefore, N-myristoylated short peptide-presenting MHC class
I alleles may be of evolutional signiﬁcance.
Methods
Generation of monoclonal antibodies. The rhesus macaques (Macaca mulatta)
used in this study were treated humanely in accordance with institutional
regulations, and the experimental protocols were approved by the Committee for
Experimental Use of Non-human Primates at the Institute for Virus Research and
at the Primate Research Institute, Kyoto University. Rhesus macaque monocytes
were isolated from PBMCs using MACS MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) conjugated with cross-reactive anti-human CD14 Abs. After
immunizing BALB/c mice with these monocytes, spleen cells were obtained and
fused with SP2/0 myeloma cells using the standard polyethylene glycol method35.
Culture supernatants of the hybridoma clones were tested at a dilution of 1:1 for
their reactivity to rhesus macaque monocytes by ﬂow cytometry and positive clones
were subjected to T-cell assays to assess blocking activities.
Isolation of MHC class I genes. Total RNA was extracted from rhesus macaque
monocytes using the RNeasy mini kit (Qiagen, Hilden, Germany) and ﬁrst-strand
cDNA was synthesized from 3 mg of RNA using the SMART cDNA Library
Construction kit (Clontech, Palo Alto, CA), followed by a treatment with RNaseH
(Invitrogen, Carlsbad, CA). DNA samples were incubated with 0.1 nmol of a
biotinylated oligo-probe (50-GAG GCC ACC CTG AGG TGC TGG GCC CTG-30 ,
speciﬁc for the conserved MHC class I a3 domain) for 5min at 95 C and then for
2 h at 55 C, and probe-bound DNAs were captured by an incubation for 1 h at
room temperature with 150 mg of Streptavidin–Dynabeads (Invitrogen). After
magnetic separation, DNA was used as a template for PCR ampliﬁcation. PCR was
performed with the Advantage2 DNA polymerase (Clontech) according to the
manufacturer’s instructions. The DNA samples were treated sequentially with
proteinase K and SﬁI, followed by cloning into the pEXP-Lib vector (Clontech).
Each of the isolated DNA clones was transfected into the rhesus macaque kidney
epithelial cell line LLC-MK2 using the Lipofectamine 2000 reagent (Invitrogen)
and the cell transfectants were used as Ag-presenting cells in T-cells assays with
2N5.1 as responder cells36.
Generation of the C14nef5-loaded Mamu-B*098 complex. Recombinant
proteins were prepared as described previously with some modiﬁcations37.
Brieﬂy, DNA constructs encoding the ectodomain of Mamu-B*098 (from Gly1 to
Pro276 with the unpaired Cys167 mutated to Ser and a Met-Ala added to the
N terminus) and rhesus b2m (from Ile1 to Met99 with a Met-Ala added to the N
terminus) were synthesized and cloned into pLM1. The expression plasmids were
introduced into the E. coli Rosetta 2 (DE3) pLysS strain (Novagen, Madison, WI)
and colonies were inoculated into a Terriﬁc Broth supplemented with 50 mgml 1
ampicillin. Isopropyl-b-D-thiogalactoside was added to the culture at a ﬁnal
concentration of 0.5mM when the OD600 value of the culture reached 0.5. After an
additional 6-h culture, bacteria were harvested and lysed in a buffer containing
50mM Tris-HCl pH 8.0, 1mM EDTA, 0.1% NaN3, 10mM dithiothreitol (DTT),
100mM NaCl, 1% Triton X-100, 1% deoxycholate and 5mM MgCl2, followed by a




















Figure 4 | Interactions with the peptide chain of the lipopeptide. (a) F pockets of Mamu-B*098 (left, blue), HLA-B27 (middle, light orange) and
Mamu-B*17 (right, pink) are shown as a semi-transparent groove and side chains (lines) with an emphasis on the key side chains at position 116. Two
C-terminal amino acid residues of the ligands anchored in each F pocket are displayed as yellow sticks. (b) A hydrogen bond network was established
between Mamu-B*098 and C14nef5. The top (left) and side (right) views of the Mamu-B*098:C14nef5 complex are displayed with hydrogen bonds
(orange dashed lines). Water molecules are shown with blue spheres.
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pellets were washed twice with a wash buffer containing 50mM Tris-HCl pH 8.0,
1mM EDTA, 0.1% NaN3, 1mM DTT, 100mM NaCl and 0.5% Triton X-100, and
once with a rinse buffer containing 50mM Tris-HCl pH 8.0, 1mM EDTA, 0.1%
NaN3 and 1mM DTT. The puriﬁed inclusion bodies were then dissolved in a
buffer containing 25mM MES pH 6.0, 10mM EDTA, 6M Guanidine-HCl and
1mM DTT, and insoluble material was removed by centrifugation. The
supernatant was treated with 50mM DTT for 3 h at 37 C and aliquots were stored
at  80 C until use.
To obtain a trimer complex of B*098 heavy chains, b2m and C14nef5, the
solubilized Mamu-B*098 heavy chains (33mg) and b2m (12mg) were refolded by
rapid dilution in 1 litre of refolding buffer (100mM Tris-HCl pH 8.3, 500mM
L-arginine, 2mM EDTA, 0.5mM oxidized glutathione and 5mM reduced
glutathione) containing 5mg of C14nef5. After 48 h of continuous stirring at 10 C,
the samples were dialysed at 10 C once against 4 l of 100mM urea and twice
against 4 l of 10mM Tris-HCl pH 8.0. The refolded proteins were concentrated
with DEAE-650M (Toyopearl, Tokyo, Japan) and subjected to HiLoad 16/600
Superdex 200 pg (GE Healthcare, Milwaukee, WI) size-exclusion chromatography
and monoQ (GE Healthcare) anion exchange chromatography. The structural
integrity of the protein complex was conﬁrmed by native PAGE, circular dichroism
spectra and enzyme-linked immunosorbent assay with conformation-dependent
monoclonal antibodies to MHC class I (MB226) and b2m (MB217).
Crystallization and structure determination. Crystals were formed at 20 C by
mixing 1 ml of a 10-mgml 1 protein solution and 1 ml of a mother liquid
containing 100mM Tris-HCl pH 7.2, 2mM zinc chloride and 13% PEG 6000,
which was then cryoprotected in 20% ethylene glycol. Diffraction data were
collected at 100 K (in a cold nitrogen gas stream) on a Rigaku Saturn A200
charge-coupled device detector (Rigaku/MSC, Woodlands, TX), using synchrotron
radiation with a wavelength of 1.0 Å, at the BL26B1 station, SPring-8, Hyogo,
Japan38. The resulting data set was processed, merged and scaled using HKL-2000
(HKL Research, Charlottesville, VA)39. The complex structure was solved by
molecular replacement with Mamu-B*17 (PDB code 3RWJ) as a search model, as
implemented in the CCP4i software suite40. The model was reﬁned using the
REFMAC5 (ref. 41) and PHENIX42 software packages. The structure was
visualized and rebuilt using COOT 0.8.1 (ref. 43) and further modiﬁed on
s-weighted (2|Fo|—|Fc|) and (|Fo|—|Fc|) electron density maps. Zinc ions were
carefully placed onto the structure by calculating its abnormal dispersion. Repeated
processes of rebuilding and reﬁnement resulted in Rwork/Rfree values of 19.5 and
22.8% with 98.7% of residues being in favoured regions and 0.1% of residues being
in outliers in a Ramachandran plot implemented in COOT. The four Mamu-
B*098:C14nef5 complexes in the asymmetric unit were nearly identical (average
r.m.s.d. of 0.37 Å over 276 Ca atoms) and the structure of one representative
complex composed of chains D, E and F was described. Crystallographic images
were produced using PyMOL (DeLano Scientiﬁc, San Carlos, CA).
The accessible surface area (Fig. 2e) and molecular contacts between C14nef5
and Mamu-B*098 (Supplementary Table 1) were analysed using CCP4i. The sizes
of pocket B (composed of amino acid residues 7, 9, 22, 24, 45, 63, 66, 67, 70, 74, 97
and 99) and pocket F (composed of amino acid residues 77, 80, 81, 84, 95, 116, 117,
118, 123, 124, 143, 146 and 147) were calculated using the CASTp web server
(http://cast.engr.uic.edu)44 with a probe radius of 1.4 Å (Figs 3b and 4a,
respectively). The r.m.s.d. values over all the Ca atoms in the a1 and a2 domains
after the superimposition of Mamu-B*098 with HLA-B27 (1K5N), Mamu-B17
(3RWG), HLA-A2 (3MRE), HLA-E (3BZE), HLA-G (3KYO), MR1 (4L4T), HFE
(1A6Z) and CD1a_ENREF_38 (4X6F) were calculated (Fig. 2b). The spatial
conﬁguration of C14nef5 bound to Mamu-B*098 was compared with that of
peptides bound to HLA-A1 (3BO8), HLA-A2 (3MRE), HLA-A3 (3RL1), HLA-A11
(1X7Q), HLA-A68 (4HX1), HLA-B8 (4QRS), HLA-B15 (1XR9), HLA-B27 (1K5N),
HLA-B39 (4O2C), HLA-B44 (1M6O), HLA-B51 (1E27), HLA-B53 (1A1M),
HLA-B57 (2BVP) and HLA-Cw4 (1QQD) (Fig. 5a). The VDW forces were
estimated by a fragment molecular orbital calculation using the PAICS programme
(Supplementary Fig. 3)45–47. Electrostatic potential was calculated using the
eF-surf server (http://ef-site.hgc.jp/eF-surf/; Supplementary Fig. 4)48.
Generation of b2 m-linked MHC class I proteins. Single-chain MHC proteins in
which b2m was linked via a Gly-Ser linker (GGGGSGGSGSGGGSS) to the ecto-
domain of either Mamu-B*098 or Mamu-A*02, followed by a biotinylation sequence
peptide (LHHILDAQKMVWNHR), were also expressed in E. coli and were puriﬁed
in a similar manner to the trimer complex of Mamu-B*098, b2m and C14nef5.
The b2m-linked Mamu-B*098 protein was refolded without C14nef5, whereas the
b2m-linked Mamu-A*02 protein was refolded in the presence of the YY9 peptide
(YTSGPGIRY). These recombinant proteins (3mg) were biotinylated by being
incubated for 12 h at 20 C with 2mg of BirA enzyme (Sigma-Aldrich, St Louis, MO)
in a biotinylation buffer containing 100mM Tris-HCl pH 8.0, 5mM MgCl2, 4.5mM
ATP and 4mM D-biotin, and were puriﬁed by size-exclusion chromatography.
Generation of a soluble TCR dimer. TCR dimers were generated by the disulﬁde-
linked TCR method49. DNA constructs encoding the extracellular domains of
2N5.1-derived TCRa (from Gln1 to Gly200 with Thr158 mutated to Cys) and TCRb
(from Gln1 to Asp242 with Ser169 mutated to Cys) were cloned into pET-21c(þ ),
and the expression plasmids were expressed in E. coli as described above. Puriﬁed
TCRa (15mg) and TCRb (16mg) proteins were combined in 500ml of a buffer
containing 100mM Tris-HCl pH 8.1, 400mM L-arginine, 2mM EDTA, 5M urea,
3.7mM cystamine and 6.6mM cysteamine, and then incubated for 24 h at 10 C
with continuous stirring. The samples were dialysed three times against 4 l of 10mM
Tris-HCl pH 8.0 and puriﬁed as described above. A non-reducing SDS–PAGE
analysis conﬁrmed disulﬁde bond formation between the TCRa and TCRb chains.
T-cell assays. Streptavidin-coated 96-well plates (Thermo Scientiﬁc, Hudson, NH)
were overlaid with 10 mg of the biotinylated b2m-linked Mamu-B*098 and Mamu-
A*02 proteins, and lipopeptide Ags (1mg) were loaded by an overnight incubation
at 37 C. The wells were then washed extensively and T cells (5 104 per well) were
added. After a 24-h incubation at 37 C, aliquots of the culture supernatants were
collected and the amount of IFN-g released into the medium was measured by a
human/monkey IFN-g enzyme-linked immunosorbent assay kit (Mabtech, Nacka
Strand, Sweden).
Biolayer interferometry and SPR-binding assays. The binding of ligands to
MHC class I molecules was analysed using the Octet RED96 system equipped with a
streptavidin-conjugated biosensor (Pall ForteBio, Menlo Park, CA) according to the
manufacturer’s instructions. Biotinylated b2m-linked Mamu-B*098 and Mamu-
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Figure 5 | Spatial conﬁguration of MHC class I-presented C14nef5 and
conventional peptides. (a) A stereo view of C14nef5 (thick yellow sticks)
bound to Mamu-B*098 overlaid with an array of representative 9-mer
peptides (thin lines) bound to MHC class I molecules is shown. (b) The
space coordinates of the main chain of MHC class I-bound peptides were
determined for 280 registered MHC class I:peptide complexes and the
mean values on the x axis (parallel to two a-helixes), y axis (vertical to the x
axis and parallel to the line connecting the centres of two a-helixes) and z
axis (vertical to the x axis and y axis) are shown with open circles. Error
bars indicate s.d. The space coordinates of Mamu-B*098-bound C14nef5
were also determined and are shown with closed circles. It is worth noting
that the three C-terminal residues (Ala3, Ile4 and Ser5) of C14nef5 and
corresponding amino acid residues of conventional peptides exhibited a
similar spatial conﬁguration, whereas the two N-terminal residues (Gly1 and
Gly2) of C14nef5 deviated in the y- and z axes from the position of the
corresponding residues of conventional peptides.
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B5.0 nm. The sensors were treated with 10mgml 1 biocytin for quenching,
followed by incubation with lipopeptides (10mM) in an assay buffer (20mM
Tris-HCl pH 7.5, 150mM NaCl and 2% dimethylsulfoxide). After 45min, the sen-
sors were placed in the assay buffer without lipopeptides and incubated for an
additional 30min. Assays were performed at 30 C. SPR-binding assays were per-
formed to assess TCR interactions using the Biacore 3000 (GE Healthcare) according
to the manufacturer’s instructions. Lipopeptide Ag-loaded MHC molecules were
immobilized on the sensor chip SA and then incubated at 30 C with serially diluted
2N5.1 TCR proteins for 90 s (for association), followed by an incubation at 30 C in
an analyte-free assay buffer (20mM Tris-HCl pH 7.5, 150mM NaCl and 1mM
MgCl2) for 120 s (for dissociation). After reference subtraction, binding signals were
analysed using the BIAevaluation 3.1 software. The equilibrium-dissociation con-
stant (KD) was obtained by a global curve ﬁtting method.
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